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Abstract
Background: Using a human small cell lung cancer (SCLC) xenografted in nude mice, we have
previously reported enhanced tumor growth inhibition following chemotherapy in combination
with imatinib (STI571). We therefore investigated the in vivo impact of imatinib on the
pharmacokinetics and efficacy of chemotherapy.
Methods: Two different human tumors were used: SCLC6 small cell lung cancer xenografted in
nude mice, and LY-3 EBV-associated human B-cell lymphoma xenografted in SCID mice. Plasma,
urine, and fecal concentrations of etoposide (VP16) were determined by a validated high
performance liquid chromatography method. Plasma concentrations of ifosfamidewere determined
by a validated gas chromatography assay with nitrogen-phosphorus detection.
Results: Slight tumor growth inhibition was induced by imatinib administered alone in one in vivo
EBV-associated B-cell lymphomatous xenograft. In contrast, an increase of the chemotherapy-
induced antitumor effect was observed in the lymphoma model but not in a small cell lung cancer
model when mice bearing human xenografted tumors were treated concomitantly by imatinib and
chemotherapy. This antitumor effect was not influenced by concomitant administration of
fluconazole. The AUC0-3 h (Area Under the concentration-time Curve) of etoposide was
increased when mice were treated with etoposide + imatinib due to decreased fecal excretion. In
contrast, imatinib did not appear to influence the urinary excretion of etoposide, and concomitant
administration of the CYP3A4 inhibitor, fluconazole, with imatinib did not modify the
pharmacokinetics of etoposide plus imatinib alone.
Conclusion: Altogether, these results therefore justify further prospective phase I and II clinical
trials with combinations of etoposide-based chemotherapy and imatinib in patients with certain
cancers, such as malignant lymphoma, with careful toxicologic monitoring.
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Background
The tyrosine kinase inhibitor imatinib (STI571), belong-
ing to the 2-phenylaminopyrimidine class, selectively
inhibits BCR/ABL [1], PDGFR ("Platelet-Derived Growth
Factor receptor"), c-kit [2], and c-fms ("Macrophage col-
ony-stimulating factor receptor")[3] kinase activity. As
imatinib is commonly used without chemotherapeutic
agents, few reports have evaluated the therapeutic effect of
concomitant administration of imatinib and chemother-
apy either in mice xenografted tumors or cancer patients.
Using a human small cell lung cancer (SCLC) xenograft in
nude  mice, we previously reported enhanced tumor
growth inhibition following chemotherapy (etoposide +
ifosfamide or topotecan) in combination with imatinib
and showed that this effect was not dependent on c-kit
expression level [4]. The increase of conventional antine-
oplastic agent-induced tumor growth inhibition was also
exclusively observed when imatinib and chemotherapy
were administered concomitantly. Various mechanisms
can be proposed to explain this effect, namely (1) an
increase of drug uptake by imatinib-induced reduction of
tumor interstitial fluid pressure and an increase of tran-
scapillary transport [5], (2) inhibition of tumor angiogen-
esis combined with the antitumor effect of chemotherapy
[6-8], and (3) certain intracellular events induced by the
two concomitant therapeutic modalities that remain to be
determined.
However, our in vivo experiments showed a higher toxicity
of combined imatinib and chemotherapy than for imat-
inib or chemotherapy alone, exclusively when both treat-
ments were administered concomitantly. Various
mechanisms for the toxicity of combined therapy can be
proposed, particularly pharmacokinetic interactions
between imatinib and chemotherapeutic agents that
could also explain the increase of chemotherapy-induced
tumor growth inhibition, as numerous data have shown
that imatinib induces cytochrome p450 inhibition and
that this inhibition decreases elimination of chemothera-
peutic agents such as etoposide, ifosfamide, and topote-
can [9-12]. In order to explore these pharmacokinetic
interactions, we therefore investigated the in vivo impact
of imatinib on the pharmacokinetics of chemotherapy
and its efficacy on two different human cancers
xenografted into immunodeficient mice: a SCLC [4] and
an EBV-associated B-cell lymphoproliferation [13]. We
showed that imatinib significantly increases the AUC
(Area Under the concentration-time Curve) of etoposide
in mice via a decrease of its fecal excretion. Finally, in one
of the two xenografted models used, we confirmed the
imatinib-induced increase of tumor growth inhibition
after chemotherapy with agents such as etoposide (VP16)
and gemcitabine. These results therefore support the initi-
ation of further prospective phase I and II clinical trials
combining etoposide-based chemotherapy and imatinib
in cancer patients, such as malignant lymphoma patients,
with careful toxicologic monitoring.
Methods
In vivo experiments in immunodeficient mice bearing 
human tumors
Female nude or SCID mice, weighing 20 g to 30 g, 6–8
weeks old, were bred in the animal facilities (Institut
Curie, Paris, France), maintained under specific pathogen-
free conditions with artificial lighting (12-hour light/12-
hour dark cycle) and fed with a regular diet and water ad
libitum. The care, housing, and handling of the mice were
performed in accordance with the recommendations of
the French Ethics Committee and under the supervision
of authorized investigators. For curative therapeutic trials,
the tumor-bearing mice were randomly divided into
equivalent groups of 6 to 8 animals and mice were treated
at different times after transplantation.
Two different human tumors were used: the SCLC6 small
cell lung cancer xenografted in nude mice [4], and the LY-
3 EBV-associated human B-cell lymphoma xenografted in
SCID mice [13]. STI571 (gift from Novartis Pharma SAS,
Rueil-Malmaison, France) was diluted in 150 µl of H2O
and administered at a total dosage of 70 mg/kg per day in
one intraperitoneal injection on different days, as indi-
cated. Etoposide (VP16)(Pierre Fabre, Boulogne, France)
and ifosfamide (Baxter, Paris, France) were diluted in 200
µl of 0.9% sodium chloride and administered at a dose of
12 mg/kg and 90 mg/kg, respectively, in one daily intra-
peritoneal injection on days 1 to 3 of treatment. Flucona-
zole (PFIZER Paris, France) was diluted in 400 µl of water
and administered at a total dosage of 40 mg/kg per day in
one intraperitoneal injection on days 1 to 3 of treatment.
Gemcitabine (Lilly France SAS, Suresnes, France) was
diluted in 150 µl of 0.9% sodium chloride and adminis-
tered in one weekly intraperitoneal injection at a dosage
of 60 mg/kg per day. The control group received 0.9%
sodium chloride injections according to the same sched-
ule as experimentally treated mice.
All mice were weighed once weekly. Tumor growth was
monitored by measuring two perpendicular diameters
with calipers. Tumor volume (V) and relative tumor vol-
ume (RTV) were calculated as follows:
V = a2 × b/2,
where a is the width (large diameter) and b the length
(small diameter) of the tumor in millimeters.
RTV = Vx/Vi,
where Vx is the mean tumor volume in cubic millimeters
at any given time and Vi is the mean initial tumor volumeBMC Pharmacology 2007, 7:13 http://www.biomedcentral.com/1471-2210/7/13
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in cubic millimeters at the start of treatment [14]. Mice
were ethically sacrificed when the tumor volume reached
2,500 mm3 in the control group.
Pharmacokinetics of etoposide (VP16) and/or ifosfamide in 
mice
In order to evaluate pharmacokinetic interactions
between STI571 (imatinib) and chemotherapeutic agents
(etoposide and ifosfamide), various concentrations of the
two cytotoxic agents were measured. Plasma, urine, and
fecal concentrations of etoposide were determined by a
validated high performance liquid chromatography
(HPLC) method with U.V. detection [15]. Standard sam-
ples were prepared from a stock solution of 1000 µg/ml
etoposide which was added to drug-free pooled plasma or
urine. The analytes were extracted from plasma, urine and
feces by liquid-liquid extraction into aqueous phase with
dichloromethane. All 24-hour fecal samples were weighed
and homogenized with 1 ml of water. Plasma concentra-
tions of ifosfamidewere determined by a validated gas
chromatography assay (GC) with nitrogen-phosphorus
detection [16]. The analytes were extracted from plasma
and urine by liquid-liquid extraction into aqueous phase
with ethyl acetate.
Evaluation of c-kit mRNA expression
Total RNA extraction and cDNA synthesis were performed
as previously described [17]. Briefly, total RNA was
extracted from crushed tumor samples (SCLC 6, SCLC 61,
SCLC 74 and SCLC 108) by RNA plus® kit (Bioprobe,
France). One µg of total RNA was reverse transcribed in a
final volume of 20 µL containing 1× reverse transcriptase
buffer [500 mM of each deoxynucleotide triphosphate, 3
mM MgCl2, 75 mM KCl, and 50 mM Tris-HCl (pH 8.3)],
10 units of RNase inhibitor (Promega, Madison, WI), 10
mM DTT, 50 units of Superscript II RNAse H-reverse-tran-
scriptase (Life Technology, Inc), and 1.5 mM random hex-
amers (Pharmacia, Uppsala, Sweden). The reaction mix
was then incubated at 42°C for 30 min.
C-kit transcripts were quantified using real-time quantita-
tive reverse transcription-PCR assays. Primers and probes
were chosen with the assistance of Primer Express soft-
ware (Applied Biosystems, Foster City, CA-IC). The nucle-
otide sequence was then blasted against dbEST and nr (the
non-redundant set of the GenBank, EMBL and DDBJ data-
base sequences) to confirm the total gene specificity of the
nucleotide sequences chosen as primers at probes. Each
primer couple was positioned in different exons (i.e.
exons 20–21 for c-kit gene) of the gene in order to avoid
amplification of contaminating genomic DNA. PCR reac-
tions were performed using an ABI Prism 7700 Sequence
Detection System (Applied Biosystems, Foster City, CA-
IC) and Core Reagent Kit (Eurogenetec, Belgium). Real-
time detection was performed using oligonucleotide
probes containing a fluorescent dye at its 5'-end and a
quencher at its 3'-end (for c-kit mRNA quantification).
Fluorescent probes were synthesized by Applied Biosys-
tems, and primers were synthesized by Invitrogen (Pais-
ley, UK). The nucleotide and probe sequences are as
follows: c-kit: upper primer 5'-aagcagatttcagagagcacca-3',
lower primer 5'gctgccgacagaattgatcc-3' and probe 5'actc-
caacttagcaaactgcagccccaa-3'. Transcripts of TBP (TATA
box-binding protein)[18] were also quantified as endog-
enous RNA of reference genes to normalize c-kit expres-
sion.
The thermal cycling conditions comprised an initial dena-
turation step at 95°C for 10 min, then 40 cycles at 95°C
for 15 sec and an annealing temperature depending upon
the target. For c-kit quantification, a calibration curve for
mRNA expression was generated using serial dilutions of
L174 human colon carcinoma cell line mRNA expressing
high levels of c-kit mRNA to assess PCR efficiency. All
measurements were performed under blind conditions
and in duplicate. Two negative "non-template" controls
were included in each amplification run.
Results were expressed as N-fold differences in target gene
expression relative to the reference gene (either TBP) and
the calibrator was called "Ntarget". It was determined as
follows: N target = E(∆Ct sample-∆Ct calibrator), where the ∆Ct
values of the sample and calibrator were determined by
subtracting the average Ct values of the target gene from
the average value of the reference gene (TBP) and E is the
efficiency of PCR measured using the slope of the calibra-
tion curve. For c-kit mRNA quantification, the positive
control, corresponding to a case of uveal melanoma
exhibiting strong c-kit overexpression, was assessed with
SCLC samples.
Statistical analysis
Statistical analysis of variance (ANOVA test) was per-
formed to assess the difference between AUC0–3 h (Area
Under the concentration-time Curve) of etoposide in the
various treatments. A Mann-Whitney U-test was used to
assess the in vivo effect of the various treatments on the
growth of xenografted tumors in nude or SCID mice. U
values were considered significant when the probability of
a difference was less than or equal to 0.05. Values were
considered significant when the probability of a difference
was less than or equal to 0.05.
Results
Impact of STI571 on the in vivo xenografted tumor growth 
of etoposide (VP16) chemotherapy
SCLC6-bearing nude mice received intraperitoneal injec-
tions of etoposide (12 mg/kg) on days 1–3, with or with-
out STI571 administered on days 1–3 by intraperitonealBMC Pharmacology 2007, 7:13 http://www.biomedcentral.com/1471-2210/7/13
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injections at a total dose of 70 mg/kg daily, and with or
without intraperitoneal injections of fluconazole (40 mg/
kg/d) on days 1–3. Each treatment was initiated on day +
6 after tumor transplantation. We observed a brief but
non-significant inhibition of SLCL6 tumor growth after
etoposide administration compared to the control group
(p = NS), and this inhibition was not increased by con-
comitant injections of etoposide + STI571 or etoposide +
STI571 + fluconazole (Figure 1A).
Antitumor activity of imatinib with or without chemotherapy in two human xenografted tumors Figure 1
Antitumor activity of imatinib with or without chemotherapy in two human xenografted tumors. (A)(C). Both 
xenografted SCLC6 (A) and LY-3 (C) tumors were treated by etoposide (VP16) alone (E) at a dosage of 12 mg/kg in one daily 
intraperitoneal injection on days 1 to 3 (▲ ), etoposide (VP16) and STI571 (E + S) administered by one daily intraperitoneal 
injection at a dose of 70 mg/kg on days 1 to 3 (■ ), etoposide (VP16) and fluconazole (E + F) at a dosage of 40 mg/kg in one 
daily intraperitoneal injection on days 1 to 3 (❍ ), or etoposide (VP16) with STI571 and fluconazole (E + S + F)(). All other 
groups included STI571 alone (S)(), fluconazole alone (F)(), and STI571 + fluconazole (S + F)() and 0.9% NaCl (● ). (B) 
Mice bearing LY-3 tumors were treated by one () daily intraperitoneal injection of STI571 (S) at a dose of 70 mg/kg from day 
1 until sacrifice of the animals. (D) Xenografted LY-3 tumors were treated by gemcitabine at a dosage of 60 mg/kg by one 
weekly intraperitoneal injection, with (G + S)(■ ) or without (G)(▲ ) STI571 administered by one daily intraperitoneal injection 
at a dose of 70 mg/kg from day 1 until sacrifice of the animals. Mice treated by STI571 alone (S) are indicated by (). All con-
trol groups received injections of 0.9% NaCl (Control)(● ). Tumor growth was evaluated by measuring the relative tumor vol-
ume (RTV), as described in "Materials and Methods". A Mann-Whitney U test was used to assess the effects of treatments on 
xenografted tumor growth.
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As previously performed for the SCLC6 tumor (Decaudin
IJC), we first evaluated the antitumor effect of STI571
alone in the SCID mice xenografted LY-3 lymphomatous
tumors. Mice bearing tumors measuring approximately
60 mm3 were treated from day 1 until sacrifice of the ani-
mals by an intraperitoneal injection of STI571 at a dose of
70 mg/kg. A slight but non-significant tumor growth inhi-
bition was temporarily observed for a few days after initi-
ation of treatment (Figure 1B). Thereafter, SCID mice
bearing LY-3 tumors were treated by intraperitoneal injec-
tions of etoposide (12 mg/kg) on days 1–3, with or with-
out intraperitoneal injection of STI571 at a dose of 70 mg/
kg on days 1–3, and with or without intraperitoneal injec-
tions of fluconazole (40 mg/kg/d) on days 1–3. Each
treatment was initiated at day + 6 after tumor transplanta-
tion. We observed a spectacular enhancement of etopo-
side-induced tumor growth inhibition by concomitant
administration of STI571 (p < 0.05), and this inhibition
was not enhanced by concomitant administration of flu-
conazole (Figure 1C). Moreover, we observed three early
deaths in the combined etoposide + STI571 group, but
not in the etoposide + STI571 + fluconazole group.
Finally, in order to confirm the value of combining
STI571 with other chemotherapy modalities, mice bear-
ing LY-3 tumors measuring approximately 60 mm3
received weekly intraperitoneal injections of gemcitabine
(60 mg/kg), with or without intraperitoneal injections of
STI571 at a total dose of 70 mg/kg daily from day 1 until
sacrifice of the animals. We observed an enhancement of
gemcitabine-induced tumor growth inhibition by con-
comitant and continuous administration of STI571 (p <
0.01)(Figure 1D).
Impact of STI571 on the pharmacokinetics of combined 
etoposide (VP16) and ifosfamide chemotherapy regimen in 
mice
To study the impact of STI571 on the in vivo pharmacoki-
netics of chemotherapy, C57 Black6 mice were treated on
days 1 to 3 by concomitant intraperitoneal injections of
etoposide (12 mg/kg/d) and ifosfamide (90 mg/kg/d),
with or without STI571 (70 mg/kg/d), and serum was col-
lected from an eye vein on days 1 and 3, 0, 1, 3 and 6
hours after injections. We observed an increase of the
Cmax of both etoposide and ifosfamide on days 1 and 3
when mice were treated by chemotherapy combined with
STI571 compared to chemotherapy alone (Table 1). To
confirm this result and to focus on etoposide pharmacok-
inetics, CD1 mice were treated on days 1–3 by intraperito-
neal injections of 12 mg/kg/d etoposide, with or without
intraperitoneal 70 mg/kg/d of STI571. Samples were col-
lected on days 1 and 3, 0.5, 1, 2 and 3 hours after injec-
tions. We observed a significant increase of the mean
AUC0–3 h (Area Under the concentration-time Curve) of
etoposide (17900 µg/l × h) when mice were treated with
etoposide + STI571 (60800 µg/l × h)(p = 0.025)(Figure
2A).
In order to evaluate the role of CYP3A4 on the pharma-
cokinetic interaction between etoposide and STI571, CD1
mice were treated on days 1–3 by intraperitoneal injec-
tions of etoposide (12 mg/kg/d), with or without STI571
(70 mg/kg/d), and with or without the CYP3A4 inhibitor,
fluconazole (40 mg/kg/d). The samples were collected on
days 1 and 3, 0.5, 1, 2 and 3 hours after injections. A sum-
mary of etoposide pharmacokinetic parameters (mean) is
(A) Mean AUC0–3 h of etoposide (VP16) in CD1 mice Figure 2
(A) Mean AUC0–3 h of etoposide (VP16) in CD1 mice. 
Area Under Curve concentration versus time of etoposide 
(VP16) was calculated between base time (0) and 3 hours 
after administration of etoposide alone or etoposide plus flu-
conazole or etoposide plus imatinib or etoposide with imat-
inib and fluconazole. (B) Concentration-time curve of 
etoposide (VP16) administered with STI571. After 
administration of etoposide (VP16) with STI571, concentra-
tions of VP16 peaked at 30.9 ± 2.1 ng/mL, followed by a bi-
exponential decline. (C) Graphical analysis between cal-
culated concentrations and observed concentrations 
of etoposide (VP16).
A
B
Table 1: Mean Cmax of etoposide (VP16) and ifosfamide 
administered alone or with imatinib
Ifosfamide Ifosfamide + imatinib
Mean Cmax 9 +/- 4.5 µg/ml 14.4 +/- 6.4 µg/ml
Etoposide Etoposide + imatinib
Mean Cmax 8.6 +/- 4.1 µg/ml 42.7 +/- 37.6 µg/mlBMC Pharmacology 2007, 7:13 http://www.biomedcentral.com/1471-2210/7/13
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presented in Table 2. We observed a highly significant
increase of the mean AUC0–3 h of etoposide (19970 µg/l ×
h) when mice were treated with etoposide + STI571 + flu-
conazole (48960 µg/l × h), as compared to either etopo-
side + STI571 (38380 µg/l × h) or etoposide + fluconazole
(23680 µg/l × h) combinations (p = 0.0003)(Figure 2A).
In both experiments, after administration of VP16 with
STI571, VP16 concentrations peaked at 30.9 ± 2.1 ng/mL,
followed by a bi-exponential decline (Figure 2B). VP16
concentrations reached 46.5 ± 6.4 ng/mL when VP16 was
administered with STI571 and fluconazole. In both cases,
the pharmacokinetic curve was best described as bi-expo-
nential as demonstrated by the concentration-time curve
of VP16 administered with STI571 (Figure 2C).
To explain the impact of STI571 on the pharmacokinetics
of etoposide, we studied the liver and kidney clearance of
etoposide by assaying the chemotherapeutic agent in
urine and feces of CD1 mice treated on day 1 by one intra-
peritoneal injection of etoposide (12 mg/kg/d) with or
without STI571 (70 mg/kg/d). Samples were collected for
24 hours after injection. We observed a significant
decrease of fecal excretion of etoposide when mice were
treated with either etoposide + STI571 (p = 0.005)(Figure
3A) or etoposide + STI571 + Fluconazole (p = 0.003) (Fig-
ure 3B). In contrast, no significant impact of STI571 was
observed on the renal clearance of etoposide, with (Figure
3C) or without fluconazole (Figure 3D).
Evaluation of c-kit mRNA expressions
The level of c-kit mRNA expression was quantified and
compared to the level of mRNA expression of a known c-
kit protein overexpressing melanoma. As previously
reported [4], the two SCLC6 and LY-3 xenografts express
very low levels of c-kit mRNA (data not shown).
Discussion
In conclusion, we have shown that imatinib increased the
AUC of etoposide in mice and that this effect was medi-
ated by a reduction of its fecal excretion. In contrast, imat-
inib did not appear to influence the urinary excretion of
etoposide, probably due to sample collection conditions,
and concomitant administration of the CYP3A4 inhibitor
fluconazole with imatinib did not modify the pharmacok-
inetics of etoposide plus imatinib alone. We also demon-
strated a slight tumor growth inhibition induced by
imatinib administered alone in one in vivo EBV-associated
B-cell lymphomatous xenograft, and this effect was
observed despite the absence of c-kit receptor mRNA
expression. Finally, when mice bearing human
xenografted tumors were treated concomitantly by imat-
inib and chemotherapy, an increase of the chemotherapy-
induced antitumor effect was observed in the lymphoma
model but not in a small cell lung cancer model, and this
antitumor effect was not influenced by concomitant
administration of fluconazole.
Our in vivo B-cell lymphoma studied by RT-PCR was neg-
ative for c-kit mRNA expression. This result was concord-
ant with that reported in the literature, where c-kit
expression, studied by RT-PCR or immunohistochemical
methods, was mainly observed in multiple myeloma,
CD30-positive anaplastic large cell lymphoma, and
Hodgkin's disease, as shown in Table 3[19-31]. Moreover,
very few data have been published on the therapeutic effi-
cacy of imatinib on lymphoproliferative diseases. Imat-
inib demonstrated a minimal effect in anaplastic large cell
lymphoma with NPM-ALK fusion protein [32] and Hodg-
kin lymphoma [33] cell lines. In contrast, despite an in
vitro antiproliferative effect of STI571 on a multiple mye-
loma cell line [34], no response was observed in a phase
II trial of imatinib in patients with refractory/relapsed
myeloma [35].
The combination of imatinib and chemotherapy has not
yet been reported in the literature. However, despite a
large number of in vitro studies, very few data are available
on in vivo effect of combined imatinib and chemothera-
peutic agents. These reports evaluated combinations of
imatinib and zoledronate [36], troxacitabine [37], epothi-
lone B [38], and paclitaxel [39]. In our study, we showed
that the imatinib-induced increase of etoposide AUC
enhances the tumor growth inhibition of a human
xenografted lymphomatous tumor, but not that of an in
vivo human small cell lung cancer tumor. This observation
argues in favor of an increased in vivo efficacy of etoposide
combined with imatinib, showing that chemotherapy
resistance could be reversed by the combination with
imatinib in some cancer situations, such as our EBV-asso-
ciated B-cell lymphomatous model and several other
small cell lung cancer xenografts previously reported [4].
A number of published clinical studies have used various
chemotherapeutic regimens in various cancer indications.
Table 2: Pharmacokinetic parameters of Etoposide (VP16) administered alone or in combination
Etoposide Etoposide + fluconazole Etoposide + imatinib Etoposide + fluconazole + imatinib
T 1/2 (hours) 0.24 0.23 0.35 0.49
AUC (µg/L × h) 19970 23680 38380 48960
Clearance (ml/h) 0.62 0.51 0.32 0.25BMC Pharmacology 2007, 7:13 http://www.biomedcentral.com/1471-2210/7/13
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All these data are summarized in Table 4[40-50]. Because
of the heterogeneity of these series, it is impossible to
clearly define the impact of these combinations on patient
outcome. However, they provide a good overview of the
toxicities. Some observed side effects can be mainly attrib-
uted to the use of antineoplastic drugs, namely hemato-
logic toxicity, nausea and vomiting, infections, and
diarrhea, while other side effects could be attributed to the
use of imatinib, such as fatigue, peripheral edema, skin
eruptions, neuropathy, and liver dysfunction. Only one
phase I study of imatinib mesylate combined with doxo-
rubicin and gemcitabine in patients with small cell lung
carcinoma showed a high rate of dose-limiting toxicity
that required early discontinuation of the trials [47].
Conclusion
In summary, imatinib potentiates the effects of etoposide
in cancer cells such as lymphoma cell lines. These results
therefore show that further prospective phase I and II clin-
ical trials with combinations of etoposide-based chemo-
therapy and imatinib are therefore warranted in some
Fecal and urine excretion of etoposide in CD1 mice Figure 3
Fecal and urine excretion of etoposide in CD1 mice. Etoposide (VP16) levels were determined in feces (ng of etopo-
side/g of feces) when mice were treated with etoposide alone (A, B) or in combination with imatinib (B) or in combination with 
imatinib and fluconazole (B). Etoposide (VP16) levels were determined in urine (ng of etoposide/24 hours of urine) when mice 
were treated with etoposide alone (C, D) or in combination with imatinib (C) or in combination with imatinib and fluconazole 
(D).
A B
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Table 3: c-kit expression in lymphoid malignancies
Type of lymphoma Methods Positive c-kit expression/N (%) References
Multiple myeloma Flow cytometry 49/158 (31%) Kraj 2004
Multiple myeloma Flow cytometry 17/48 (35%) Li 2004
Multiple myeloma Flow cytometry 18/56 (32%) Ocqueteau 1996
Multiple myeloma Immunohistochemistry 5/31 (16%) Potti 2002
Multiple myeloma Immunohistochemistry 2/72 (3%) Lugli 2004
Cutaneous plasmacytoma Immunohistochemistry 13/13 (100%) Bayer-Garner 2003
Total MM / 104/378 (27%) /
Lymphoplasmacytic Immunohistochemistry 0/10 (0%) Lugli 2004
Lymphoplasmacytic Flow cytometry 0/7 (0%) Kraj 2004
Mantle cell L. Immunohistochemistry 2/17 (1%) Potti 2002
Lymphomatoid papulosis Immunohistochemistry 0/18 (0%) Rassidakis 2004
DLBCL Immunohistochemistry 24/65 (37%) Vakiani 2005
Total B-cell L. / 26/117 (22%) /
CD30+ anaplastic large cell L. Immunohistochemistry 7/18 (39%) Brauns 2004
CD30+ anaplastic large cell L. Immunohistochemistry 11/16 (69%) Pinto 1994
CD30+ anaplastic large cell L. Immunohistochemistry 1/78 (1%) Rassidakis 2004
Lymphomatoid papulosis Immunohistochemistry 0/18 (0%) Rassidakis 2004
Total CD30+ L. / 19/130 (15%) /
Nasal NK/T-cell L. Immunohistochemistry 0/36 (0%) Li 2006
Cutaneous T-cell L. Immunohistochemistry 2/8 (25%) Brauns 2004
Mycosis fungoides Immunohistochemistry 6/18 (33%) Brauns 2004
Sezary's syndrome Immunohistochemistry 3/5 (60%) Brauns 2004
Total T-cell L. / 11/67 (16%) /
Hodgkin's disease Immunohistochemistry 11/21 (52%) Pinto 1994
Hodgkin's disease Immunohistochemistry 0/87 (0%) Rassidakis 2004
Hodgkin's disease Immunohistochemistry 0/342 (0%) Zimpfer 2004
Total HD / 11/450 (2%) /
Abbreviations: L., lymphoma; MM, multiple myeloma; DLBCL, diffuse large B-cell lymphoma; HD, Hodgkin's disease.
Table 4: Toxicities of imatinib combined with chemotherapy in human cancers
References N Treatment protocol Main toxicities
40 30 STI 400 mg/d + AraC 20 mg/m2/d15–28. * Hematologic.
* Nausea-vomiting.
* Fatigue.
* Abdominal pain.
* Edema.
41 22 STI 300–800 mg/d + anagrelide 0.5–4 mg/d. * Hematologic.
* Peripheral edema.
* Fatigue.
* Skin rash.
42 28 STI 600 mg/d + docetaxel 20–45 mg/m2/d1,8,15,22. * Hematologic.
* Nausea.
* Fatigue.
43 20 STI 400 mg/d + hyper-CVAD. * Hematologic.
* Infections.
44 30 STI 400 mg/d + hydroxyurea 1 g/d. * Edema.
* Abdominal pain.
45 20 STI 400/600 mg/d + daunorubicin 50 mg/m2/d1–3 + vincristine 2 mg d1,8,15,22 + prednisolone 60 mg/m2/d1–28 + L-asparaginase 
4000 U/m2/d17–28.
* Hematologic.
* Hyperbilirubinemia.
46 33 STI 400/500 mg/d + hydroxyurea 1 g/d. * Hematologic.
47 9 STI 300–400 mg/d + doxorubicin 50–60 mg/m2/d1. * Hematologic.
* Nausea-vomiting.
* Reduction of LVEF.
* Fatigue.
47 7 STI 300–400 mg/d + gemcitabine 700–800 mg/m2/d1,8,(15).*  H e m a t o l o g i c .
* Fatigue.
48 9 * STI 300–600 mg/d + irinotecan 65 mg/m2 d1,8 + cisplatin 30 mg/m2 d1,8.
* STI 300–800 mg/d + irinotecan 60 mg/m2 d1,8,15 + cisplatin 60 mg/m2 d1.
* Hematologic.
* Diarrhea.
* Thrombosis.
* Electrolyte disorder.
49 31 STI 800 mg/d + vincristine 2 mg d1,8,15,22 + dexamethasone 40 mg d1,2,8,9,15,16,22,23.*  H e m a t o l o g i c .
* Infections.
* Neuropathy.
50 80 STI 600 mg/d + cyclophosphamide 1200 mg/m2/d1 + daunorubicin 50 mg/m2/d1–3 + vincristine 1.3 mg/m2/d1,8,15,22 + 
prednisolone 60 mg/m2/d1–21.
* Hematologic.
* Nausea.
* Liver dysfunction.
Abbreviations: Hyper-CVAD, cyclophosphamide + vincristine + doxorubicin + dexamethasone + methotrexate + cytarabine; LVEF, left 
ventricular ejection fraction.BMC Pharmacology 2007, 7:13 http://www.biomedcentral.com/1471-2210/7/13
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cancer patients, such as malignant lymphoma patients,
with careful toxicologic monitoring.
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